Topac

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Topac

Topac is a trade name for an oral medicinal product whose primary component is the powerful drug substance Diclofenac, which is specifically classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This medication is a synthetic compound, chemically defined as a Phenylacetic Acid Derivative, and is prepared for Oral Administration to achieve systemic effects throughout the body.


Property Description
Active ingredient Diclofenac (Sodium or Potassium salt)
Form Oral Tablet (including Delayed-Release)
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common use Relief of pain, inflammation, and fever
Origin Synthetic (Phenylacetic Acid Derivative)

What Type of Medicine is Topac? (Identity and Classification)

Topac is a type of pain and inflammation reliever that belongs to the Nonsteroidal Anti-Inflammatory Drug (NSAID) class. The core active compound, Diclofenac, functions as an effective Cyclooxygenase Inhibitor, providing relief through targeted action against the biochemical cascade that causes physical symptoms. This Diclofenac substance is available as either the Diclofenac Sodium or Diclofenac Potassium salt and is provided to patients most commonly in the form of an Oral Tablet, including specialized Delayed-Release or Extended-Release formulations. Diclofenac is recognized for its anti-inflammatory properties and its use in managing acute discomfort, assisting in the reduction of pain associated with swelling.

Composition: Single Ingredient vs. Combination Products

The formulation of Topac is available both as a Single-Ingredient Product containing only Diclofenac, and often as a Combination Product to enhance therapeutic scope. These Combination Products frequently include additional active substances, such as Paracetamol (Acetaminophen) for enhanced analgesic effects, or the enzyme Serratiopeptidase to contribute to the management of inflammatory swelling. The purpose of offering these variations is to utilize a synergistic approach, where multiple active ingredients work through different pathways to achieve a broader, more comprehensive symptomatic benefit than a single agent could alone. This dual or triple-ingredient approach in formulations like Topac is utilized for providing effective symptomatic relief across various presentations of acute inflammation and pain.

What is Topac's General Purpose? (Fundamental Action)

The general purpose of Topac is to provide comprehensive relief by addressing the three core physical manifestations of the inflammatory process. The medication delivers a powerful triple-action effect: it is an Analgesic that mitigates pain, an Anti-inflammatory Agent that reduces swelling and redness, and an Antipyretic that helps lower elevated body temperature. By inhibiting the synthesis of Prostaglandins, which are essential mediators of pain and fever, the medicine generally helps relieve musculoskeletal discomfort and symptoms of acute inflammation. Diclofenac is characterized by its action across these three domains, reducing general pain and inflammatory symptoms, for instance, in the typical use scenario of managing temporary discomfort and associated swelling following a minor strain or similar inflammatory event.

What side effects are possible with Topac?

Possible Side Effects and Safety Information

Topac, which contains the Nonsteroidal Anti-Inflammatory Drug (NSAID) Diclofenac, is associated with an official safety profile characteristic of its class, documented by regulatory authorities. The profile includes mandatory warnings regarding Serious Cardiovascular Thrombotic Events (such as myocardial infarction and stroke) and Serious Gastrointestinal Adverse Events (including bleeding, ulceration, and perforation), which can be fatal.

Regulatory safety information is categorized by the system affected and the frequency observed in trials:

System-Organ Class Common Adverse Reactions (ge 1%)
Gastrointestinal Nausea, vomiting, diarrhea, indigestion, abdominal pain, flatulence, anorexia.
Nervous System Headache, dizziness.
Hepatobiliary Elevation of liver enzymes.

Serious reactions also include severe hepatic events (liver failure), severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), and anaphylactic reactions.

Safety Constraints and Population Notes

The risk of serious adverse events is noted to increase with the duration of use and may be more pronounced at higher doses. Regulatory standards require the use of the lowest effective dose for the shortest duration possible to minimize these risks. The medicine is contraindicated for the treatment of pain following coronary artery bypass graft (CABG) surgery. Additionally, official labeling specifies that older adults are at a greater risk for serious gastrointestinal adverse events, and use should be avoided in pregnant patients starting at 30 weeks' gestation due to the risk of fetal harm. This structure outlines the official limitations and vulnerabilities associated with this medicine.

Overdose and Emergency Response

Topac Overdose and When to Seek Help


Documented Manifestations and Severe Outcomes

The official regulatory profile for Topac (Diclofenac) overdose indicates that symptoms primarily involve the gastrointestinal (GI) and central nervous systems (CNS). Documented manifestations include epigastric pain, nausea, vomiting, and diarrhea, along with CNS effects such as drowsiness, headache, and confusion. Regulators emphasize that an overdose carries the risk of severe, life-threatening outcomes. These include major gastrointestinal perforation or bleeding, acute renal failure, and neurological complications like convulsions and coma. It is specifically noted that serious GI events have more serious consequences in the elderly.


Emergency Action and Supportive Measures

Due to the systemic risks, the regulatory guidance is to seek immediate medical attention for all suspected overdosages. The medicine should be discontinued immediately if any signs of GI bleeding or a hypersensitivity reaction appear. Management of an overdose is symptomatic and supportive, as no specific antidote is known. Procedures to prevent further absorption, such as gastric lavage and administration of activated charcoal, are officially described in regulatory documents.

Therapeutic Uses of Topac

What Topac Treats: Main Uses and Benefits

Topac may assist with providing supportive relief in conditions involving heightened neurological activity and related systemic imbalances. The therapeutic scope is relevant for managing symptoms in areas such as certain seizure disorders and for reducing the frequency of migraine headaches. The medication is considered relevant in conditions involving episodic or fluctuating manifestations, and may also be part of symptomatic management in addressing related metabolic and appetite concerns. It is applied across domains where additional symptomatic support is needed for symptoms that create noticeable physiological strain, often used during phases when symptoms become more noticeable.

It provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms. This benefit focuses on helping patients cope more steadily with difficult episodes and assisting with maintaining functional stability.


Quick Fact: Relief for Recurring Head Pain The medicine may assist with managing the frequency and intensity of recurring neurological discomfort, providing supportive relief when episodes become disruptive.


Eligibility and Restrictions for Use

Topac (topiramate) is a prescription medicine with specific requirements for patient eligibility based on age, clinical condition, and physiological status.

Contraindicated Populations

Use of Topac is formally contraindicated (must not be used) in patients with known hypersensitivity to the drug or any of its components.

Age and Indication Eligibility

Indication Minimum Age for Use
Epilepsy (Monotherapy/Adjunctive) 2 years of age and older
Migraine Prophylaxis 12 years of age and older

Conditions and States Requiring Special Consideration

  • Pregnancy: The use of Topac is restricted in pregnant women due to an increased risk of major birth defects, including cleft lip and/or palate, and potential neurodevelopmental risks to the fetus. For migraine prevention, use during pregnancy is formally contraindicated by some regulatory bodies. Females of reproductive potential must be counseled on risks and should use effective contraception.
  • Renal Impairment: Patients with reduced kidney function (Creatinine Clearance <70 mL/min) require special consideration, including a dosage adjustment, due to how the drug is cleared from the body. Geriatric patients may also require dose adjustments.
  • Concomitant Use: Use is restricted for patients who have a history of metabolic acidosis and are simultaneously taking the drug metformin; this specific combination is a formal contraindication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Topac, which contains the active ingredient Diclofenac (an NSAID), has several officially documented interactions that govern its co-administration with other substances as stated in regulatory documents.

Documented Pharmacodynamic and Bleeding Risks

Co-administration with agents that increase bleeding risk is a major regulatory concern. These include Anticoagulants (such as Warfarin), Anti-platelet agents (including low-dose Aspirin), Systemic Corticosteroids, and SSRIs/SNRIs. Using Topac with these medicines significantly compounds the risk of serious gastrointestinal bleeding or ulceration.

Exposure Alteration and Clearance

Certain medicines are documented to alter the concentration of Diclofenac or drugs co-administered with it. The strong CYP inhibitor Voriconazole is known to substantially increase the systemic exposure of Diclofenac. Conversely, Diclofenac may increase the plasma concentrations of medicines like Lithium and Digoxin, potentially leading to elevated levels of those co-administered drugs.

Contraindicated Use and Restrictions

Topac is formally contraindicated for the management of pain in the setting of Coronary Artery Bypass Graft (CABG) surgery, and its use with other systemic NSAIDs should generally be avoided. For patients taking low-dose anti-platelet Aspirin, specific Diclofenac formulations may require the Aspirin to be administered at least 2 hours prior to Topac to minimize interaction.

Population and Product-Specific Cautions

In the elderly or those with impaired renal function, concurrent use with ACE Inhibitors or ARBs requires monitoring due to the potential for renal function deterioration. Additionally, the risk of gastrointestinal bleeding from interactions is noted to be more serious in elderly patients.

Mechanism of Action

How Topac Works: Mechanism of Action

Topac exerts its action by functioning as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes (COX-1 and COX-2) across the body. This mechanistic domain is a key component because the blockage prevents the synthesis of prostaglandins, which are critical lipid compounds involved in local processes following cellular membrane disturbance.

The core mechanistic action leads to the reduction of local pro-inflammatory and nociceptive signaling. By reducing the local concentration of sensitizing prostaglandins, the drug reduces the magnitude of peripheral afferent signaling. This results in a significant physiological consequence: a reduction in prostaglandin-mediated sensory afferent sensitization and the modulation of localized vascular and cellular permeability changes.

The drug's impact on prostaglandin production represents an action early in the cascade within humoral signaling dynamics. This modification of the eicosanoid pathway restricts the magnitude of downstream mediator activity, thereby affecting the homeostasis of targeted physiological pathways.

Dosage and Administration Information

How to Use Topac (Topiramate)

Topac is a medicine administered solely through the oral route in the form of tablets or sprinkle capsules, following standardized protocols for dosing and schedule. The administration process is structured by a gradual titration of the dose, and is generally completed by taking the total daily amount in two divided doses.

Official Administration Guidelines

Feature Procedural Instruction
Dosing Schedule Initial dose is low and is then gradually increased in weekly increments until the target maintenance dose is reached. The maximum adult dose for epilepsy is 400 mg/ day.
Timing & Food The medicine may be taken without regard to meals, as food does not alter how the body absorbs the active substance.
Preparation Tablets must be swallowed whole. The contents of the sprinkle capsules may be sprinkled onto a small amount of soft food and swallowed immediately without chewing.

Population-Specific Use

Official instructions require specific dose modifications for certain groups. For adults with moderate to severe renal impairment (CrCL ≤ 70 mL/ min), the usual starting and maintenance dose must be reduced by half. Pediatric dosing (2-9 years) for adjunctive use is generally weight-based. Furthermore, the medicine should not be stopped suddenly; if discontinuation is necessary, the dose must be gradually reduced over a period of time to minimize procedural risks. These defined instructions ensure consistent administration.

Recent Clinical Evidence

Recent Clinical Evidence

Clinical research regarding Topac (or its active ingredient, topiramate) has focused primarily on its potential use in seizure management and the prevention of migraine attacks.


Mechanism and Research Focus

Studies have documented the properties and characteristics of the substance, with research investigating its characteristics and how it may influence neural activity. This includes exploring its effects on specific receptors and ion channels within the central nervous system. Further evaluations have assessed how the substance's use is associated with self-reported changes in pain reports and mobility in individuals living with chronic pain conditions. Adverse event reports and participant data on substance use were consistently documented throughout the studies.


Findings in Migraine Management

Randomized controlled trials (RCTs) have investigated the substance's potential role in reducing the frequency of migraine attacks.

Key Trial Outcomes

A large-scale, 6-month trial compared the substance to a placebo, where reports on the frequency and severity of migraine attacks were collected over the trial period. Data were also collected regarding the reported use of rescue medication among the participants who used the substance.

Research on Acute Treatment and Safety

Researchers explored the data collected when the substance was used during acute episodes of tension headache. Trial protocols for acute treatment often initiated use at the onset of reported symptoms. One trial compared the therapy to a placebo, recording differences in reported pain resolution at the 2-hour and 24-hour marks.

  • Cardiovascular Safety: Research protocols for trials often excluded participants with severe heart conditions. The scope of the research did not include a specific evaluation of this population.
  • Drug Interactions: Studies have noted potential effects when this substance was combined with certain antidepressants.

Frequently Asked Questions (FAQ)

Common questions about Topac (FAQ)


Q: What is the active ingredient in Topac and what kind of medicine is it?

Topac contains the active ingredient topiramate. According to official product information, it is classified as an antiepileptic medicine, which is a type of drug used to manage or reduce seizures. It is sometimes also referred to as an anticonvulsant, reflecting its regulatory classification.


Q: How does Topac work in the body?

Regulatory sources state that its action is believed to involve increasing the activity of the calming neurotransmitter GABA and potentially blocking some excitatory signals in the brain. These proposed actions are intended to help stabilize nerve activity, which may reduce the excessive firing associated with seizures or migraine headaches.


Q: What medical conditions is Topac approved to treat?

Regulatory documents state that Topac is approved to treat two main conditions. It is used to manage epilepsy, specifically certain types of seizures in adults and children. It is also indicated for the reduction in frequency of migraine headaches in adults.


Q: How long does it usually take for Topac to start working?

According to the official product information, the time it takes for Topac to show its full effect can vary significantly among individuals. For both epilepsy and migraine reduction, official information indicates it typically takes several weeks of consistent use to observe the intended effect, as the amount taken is increased slowly.


Q: Can I stop taking Topac if I start feeling better?

Official product information advises against abruptly stopping Topac. Stopping the medicine suddenly, especially when treating epilepsy, can increase the risk of seizures. The regulatory documents recommend that if stopping treatment is necessary, it must be done gradually using a schedule determined by a healthcare provider.


Q: What should I do if I miss taking a dose of Topac?

The official label information suggests that if a dose of Topac is missed, it can be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, the regulatory recommendation is to skip the missed dose entirely. It is important to follow the label's caution to never take two doses at the same time to compensate for a missed dose.


How should Topac be stored and disposed of?

How to Store and Dispose of Topac (Diclofenac Oral Tablets)

Official regulatory guidelines define specific storage and disposal requirements for Topac, which contains the NSAID Diclofenac, to ensure product stability and safety.


Required Storage and Protection

Requirement Specific Condition
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Do not store above 25 C.
Protection Keep the tablets away from moisture, direct light, and freezing temperatures.
Container Keep the medicine in its original container or blister packaging and ensure it is closed.

Child Safety and Disposal

Topac must be kept out of the reach of children. The primary method for discarding unused or expired tablets is by using a drug take-back program. If a take-back program is unavailable, disposal in household trash requires mixing the tablets with an undesirable substance, placing the mixture in a sealed container, and then discarding. Do not flush the medicine down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Topac found in:

A-Z Index: